Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06581640
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-30
Brief Title:
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of RelapsedRefractory Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Clinical Study of the Safety and Efficacy of Chimeric Antigen Receptor-modified T Cells Targeting BCMA for the Treatment of RelapsedRefractory Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsedrefractory multiple myeloma
Detailed Description:
Subjects who meet the eligibility criteria PBMC will be collected by blood cell separator and 50 mL of plasma will be collected for preparation of CAR-T and frozen storage of CAR-T preparations patients will be treated with autologous BCMA CAR-T transfusion and followed up for a period of 3 years with specific efficacy judgments referring to the IMWG Clinical Efficacy Evaluation Criteria
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None